Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]
, 2015 BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio +8 more
core +2 more sources
Evaluation of the relationship between lactacidemia and postoperative complications after surgery for peritoneal carcinomatosis [PDF]
Korean Journal of Anesthesiology, 2021 Background Cytoreductive surgery was developed as a treatment for peritoneal carcinomatosis. However, this surgery is associated with important complications.
Marta Soriano Hervás +7 more
doaj +1 more source
Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]
, 2019 Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica +8 more
core +1 more source
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]
, 2015 Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim +6 more
core +4 more sources
Nowotwory. Journal of Oncology, 2020 Surgical treatment of patients with peritoneal metastases in combination with Hyperthermic intraperitoneal Chemotherapy (HIPEC) and systemic treatments is applied with increasing frequency and, with correct patient qualification, allows for obtaining 5-year survival at a level of 32–52%.
Tomasz Jastrzębski +20 more
openaire +3 more sources
En-block cytoreduction for advanced ovarian cancer
Gynecologic Oncology Reports, 2023 The standard treatment of advanced ovarian, fallopian tube and peritoneal cancer is cytoreductive surgery followed by platinum-based chemotherapy (du Bois et al., 2005). This type of cancer expands through the peritoneum, which is the thin and continuous
Anastasios Pandraklakis +2 more
doaj +1 more source
Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons. [PDF]
Cancer MedABSTRACT Background Advanced ovarian cancer often presents with extensive pelvic and abdominal metastases, even malignant pleural effusion. Consequently, multivisceral resection has become the common surgical approach to achieve optimal resection of ovarian cancer.
Ye L +11 more
europepmc +2 more sources
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer [PDF]
, 2011 BACKGROUND: Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer ...
Ang, C +4 more
core +1 more source
A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma [PDF]
Revista do Colégio Brasileiro de Cirurgiões, 2017 ABSTRACT Cytoreductive surgery plus hypertermic intraperitoneal chemotherapy has emerged as a major comprehensive treatment of peritoneal malignancies and is currently the standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome as well as malignant peritoneal mesothelioma.
Batista, Thales Paulo +15 more
openaire +4 more sources
Pleura and Peritoneum, 2023 There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes ...
Falla-Zuniga Luis Felipe +7 more
doaj +1 more source